指南与共识真菌感染

EQUAL曲霉病评分验证:侵袭性肺曲霉病指南依从性管理分析

Validation of the EQUAL Aspergillosis Score by analysing guideline-adherent management of invasive pulmonary aspergillosis.
指南 / 共识 · J Antimicrob Chemother · 2021-01-01

该研究回顾性分析德国科隆大学医院103例 probable 或 proven 侵袭性肺曲霉病(IPA)患者,应用EQUAL曲霉病评分评估诊疗指南依从性。血液科组(n=76)获得67.8%的可实现分数,非血液科组(n=27)仅48.4%(P<0.001)。指南依从性管理总体为31.1%(血液科39.5% vs 非血液科7.4%)。

要点

  • EQUAL评分更适用于血液科IPA患者的管理评估,非血液科患者得分显著较低。
  • 指南依从性管理总体仅31.1%,非血液科患者依从性极低(7.4%)。
  • 两组中评分分数与生存均无相关性,需更大前瞻性研究验证。

核心结论

  • EQUAL曲霉病评分更适合评估血液科IPA患者的管理,非血液科患者适用性较差。
  • 两组中评分分数与生存均无相关性,建议基于数据修订评分。

研究设计与样本

  • 回顾性队列研究,纳入德国科隆大学医院103例probable或proven IPA患者,应用EQUAL曲霉病评分进行回顾性评分。

主要发现

  • 血液科组(n=76,73.8%)获得67.8%的可实现分数(中位15分;IQR 13-18;范围8-25),非血液科组(n=27,26.2%)获得48.4%(中位12分;IQR 9-14;范围4-18)(P<0.001)。
  • 诊断方面,血液科组获得81.3%的可实现分数(中位7分;IQR 8-10;范围3-13),非血液科组56.3%(中位7分;IQR 5-9;范围3-11)。
  • 治疗方面,血液科组获得86.3%的可实现分数(中位5分;IQR 5-5;范围0-5),非血液科组68.1%(中位5分;IQR 0-5;范围0-5)。
  • 血液科患者中,接受与未接受抗霉菌预防者的90天死亡率分别为46.0%和59.3%(P=0.004)。
  • 指南依从性管理总体见于31.1%的病例(血液科39.5%,非血液科7.4%)。

关键数值与推荐

  • EQUAL曲霉病评分总分可获得分数:血液科组中位15分(IQR 13-18),非血液科组中位12分(IQR 9-14),组间P<0.001。
  • 诊断亚组分数:血液科组中位7分(IQR 8-10),非血液科组中位7分(IQR 5-9)。
  • 治疗亚组分数:血液科组中位5分(IQR 5-5),非血液科组中位5分(IQR 0-5)。
  • 90天死亡率:血液科患者接受抗霉菌预防者46.0%,未接受者59.3%(P=0.004)。
  • 指南依从性管理比例:总体31.1%,血液科39.5%,非血液科7.4%。

临床怎么用

  • EQUAL评分可用于血液科IPA患者的指南依从性管理评估,非血液科患者需谨慎解读。
  • 非血液科IPA患者指南依从性管理比例低(7.4%),提示需加强该人群的规范化诊疗。

局限性

  • 回顾性单中心研究,样本量有限(103例),非血液科组仅27例。
  • 评分分数与生存无相关性,评分的预后价值未得到验证。
  • 作者建议基于数据修订评分,并需更大前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the diagnosis and treatment standards at the University Hospital of Cologne, Germany, by applying the EQUAL Aspergillosis Score to invasive pulmonary aspergillosis (IPA) patients. METHODS: The charts of 103 patients with probable or proven IPA at the University Hospital of Cologne were reviewed and the score retrospectively applied to all patients. RESULTS: Patients were stratified into two groups according to the underlying disease: a haematology group (n = 76, 73.8%) and a non-haematology group (n = 27, 26.2%). While the haematology group attained 67.8% of achievable score points (median: 15; IQR: 13-18; range: 8-25), the non-haematology group reached 48.4% (median: 12 points; IQR: 9-14; range: 4-18) (P < 0.001). Regarding diagnostics, haematological patients achieved 81.3% of achievable points (median: 7; IQR: 8-10; range: 3-13) and non-haematological 56.3% (median: 7; IQR: 5-9; range: 3-11). Concerning treatment, haematological patients gained 86.3% (median: 5; IQR: 5-5; range: 0-5) and non-haematological 68.1% (median: 5; IQR: 0-5; range: 0-5) of achievable points. Among the haematological patients with versus those without mould-active prophylaxis, 90 day mortality was 46.0% and 59.3% (P = 0.004), respectively. Guideline adherent management of IPA was observed in 31.1% of cases (39.5% in haematological patients and 7.4% in non-haematological). CONCLUSIONS: The EQUAL Aspergillosis Score is more suitable for evaluation of management of haematological patients compared with those without such underlying disease. In both groups there was no correlation between score points and survival. Larger prospective studies may be suitable to correlate outcome and score. A revision of the score should be considered based on the data presented.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Budin S, Salmanton-García J, Koehler P, et al. Validation of the EQUAL Aspergillosis Score by analysing guideline-adherent management of invasive pulmonary aspergillosis. J Antimicrob Chemother. 2021. PMID: 33394007. doi:10.1093/jac/dkaa518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。